The inventor of Narcan, the nasal spray that can reverse an opioid overdose, said the decision by an Oklahoma judge to hold Johnson & Johnson responsible for fueling the state's opioid crisis is a major step in the nation's effort to combat the epidemic.

While the $570 million judgment was a fraction of the $17 billion requested by the state, Dr. Roger Crystal said that it illustrates "that the states are taking this crisis very seriously."

Narcan, which administers naloxone, blocks opioid receptor sites in a person's nervous system and can reverse the effects of an overdose — if administered quickly enough.

The nasal spray was first approved by the federal Food and Drug Administration in November 2015. Since then, the product has been used countless times to reverse overdoses from opioids, which include drugs such as oxycodone, hydrocodone, morphine, and illegal fentanyl, among others.

<i>The opioid epidemic in 2017 by the numbers. Credit: U.S. Department of Health and Human Services</i>

Each dose costs roughly $37, which, Crystal said is "totally appropriate" for a drug that can save a life. Still, roughly 130 people die everyday from opioid overdoses, according to government estimates.

The Johnson & Johnson decision is a "recognition of a serious opioid crisis," Crystal said, adding that opioids have "been the biggest killer of young Americans."

Crystal added, however, that while opioid manufacturers have "significantly contributed" to the crisis, addressing the issue will require a broader restructuring of how painkillers are prescribed and how doctors approach pain management.

Monday's court ruling also coincides with International Overdose Awareness Day, which is observed every year on August 31.

Share:
More In Culture
Tips for Packing When Traveling This Holiday Season
The holiday season is nearing and lots of people have travel on their minds. Kim Appelt, fashion stylist and author of "Style for Everybody," joined Cheddar News to provide tips on how to pack like a pro to avoid one less stressful move to do ahead of a trip.
Swift Bests a Still-Strong 'Killers of the Flower Moon' at Box Office
After a record-breaking opening weekend of $92.8 million, “Taylor Swift: The Eras Tour” took in an estimated $31 million over the weekend from 3,855 locations, according to AMC Theaters. “Killers of the Flower Moon” debuted with $23 million, marking the third best opening for the 80-year-old Scorsese.
Load More